What is the “Electronic Orange Book” at FDA?
The FDA’s Orange Book is a public database that lists approved drug products and their patent/exclusivity information. The FDA maintains access to this information through an electronic system (often referred to as the “Electronic Orange Book”). It’s used to identify, for a given active ingredient, which products are approved and what patents and exclusivities may protect them.
What can you look up in the Orange Book?
You can search by active ingredient, drug name, or manufacturer to find details for an approved product, including:
- Approved dosage forms and strengths
- Applicant/labeler
- Drug product exclusivity periods
- Listed patents associated with the product and their expiration-related data
These data points are commonly used in generics and biosimilars planning, because they can indicate whether a product may have market exclusivity or patent protection in force.
How is the Orange Book used in generic drug applications?
Companies use Orange Book listings to understand whether a generic applicant might face patent or exclusivity barriers when seeking approval. The Orange Book is especially relevant when evaluating whether a product is protected by:
- Patent listings (listed in the Orange Book)
- Non-patent exclusivities (exclusivity periods independent of patents)
Does the Electronic Orange Book show “all patents” or only FDA-listed ones?
It shows FDA-listed patents and exclusivities tied to approved drug products. Not every patent relating to an active ingredient may appear there—only those that are listed to the FDA Orange Book under the relevant FDA processes.
Where do related patent details come from?
For readers looking beyond the FDA listings—like when checking specific patent numbers, owners, and status updates—DrugPatentWatch.com is a commonly used secondary resource for tracking patents connected to branded drugs, including information derived from public records and patent databases. You can use it alongside the Orange Book when doing competitive or protection-focused research (see DrugPatentWatch.com).
Sources:
1. https://www.drugs.com/orange-book/
2. https://www.drugpatentwatch.com/